MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a strategic focus on industrial safety applications in South America's mining sector. The company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments.
Leyton brings extensive experience in national drug policy and workplace safety, having helped design and implement Chile's 'Zero Tolerance' alcohol-impaired driving law as part of the country's alcohol prevention framework. He also played a role in establishing Chile's roadside drug testing program introduced in 2019. His appointment reflects MindBio's strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is critical for workplace safety and compliance.
MindBio's AI prediction model leverages over 50 million data points to predict alcohol intoxication with remarkable accuracy using only the human voice. The company is developing an enterprise platform that includes Edge-AI kiosks integrating bespoke hardware and software for detecting drug and alcohol intoxication in various enterprise environments, including mining, aviation, construction, and law enforcement. The full article detailing these developments is available at https://ibn.fm/JBNVq.
The move toward commercial deployment underscores MindBio's commitment to addressing safety challenges in high-risk industries. In South America, where mining is a cornerstone of many economies, workplace impairment is a significant concern. By deploying its AI solution, MindBio aims to provide employers with a non-invasive, real-time tool to detect impairment, potentially reducing accidents and enhancing compliance with safety regulations. The platform's ability to analyze voice patterns for signs of intoxication offers a scalable and efficient alternative to traditional testing methods.
MindBio's focus on the mining sector is strategic, given the industry's stringent safety requirements and high incidence of workplace hazards. The company's technology could also find applications in other sectors, such as aviation and construction, where impairment poses serious risks. The appointment of Leyton, with his background in policy and program implementation, is expected to accelerate adoption by navigating regulatory landscapes and building partnerships with key stakeholders.
For more information on MindBio Therapeutics and its latest developments, visit the company's newsroom at https://ibn.fm/MBQIF.
